NYSE:CHEHealthcare
Assessing Chemed (CHE) Valuation After VITAS Driven Earnings Beat And Roto Rooter Headwinds
Earnings beat and VITAS strength move Chemed into focus
Chemed (CHE) is back on investors' radar after first quarter results topped analyst revenue and non GAAP earnings expectations, helped by stronger than expected performance from its VITAS hospice unit and improved margins.
The quarter also highlighted softer conditions at Roto Rooter, including weather related disruptions and higher marketing spend, which gave investors more to consider when weighing Chemed's mix of healthcare and home...